CAL
VRCA icon

Capital Analysts LLC’s Verrica Pharmaceuticals VRCA Stock Holding History

Capital Analysts LLC’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8K Hold
1,500
– – ﹤0.01% 1305
2025
Q4 		$12K Hold
1,500
– – ﹤0.01% 1219
2025
Q3 		$6K Sell
1,500
-630
-30% -$3.8K ﹤0.01% 1290
2025
Q2 		$11K Buy
2,130
+500
+31% +$2.69K ﹤0.01% 1134
2025
Q1 		$7K Buy
1,630
+300
+23% +$1.94K ﹤0.01% 1185
2024
Q4 		$9K Buy
1,330
+700
+111% +$7.69K ﹤0.01% 1085
2024
Q3 		$9K Buy
+630
New +$28.4K ﹤0.01% 1053

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Analysts LLC's VRCA Position: Q1 2026 in Review

Capital Analysts LLC held its Verrica Pharmaceuticals (VRCA) position steady in Q1 2026 at 1,500 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1305.

Capital Analysts LLC first reported a position in VRCA in Q3 2024 and has held it in 7 quarters since. The position peaked at $12K in Q4 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Capital Analysts LLC held 1,500 shares of Verrica Pharmaceuticals worth $8K as of Q1 2026.
  • Capital Analysts LLC left its Verrica Pharmaceuticals share count unchanged in Q1 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #1305 holding.
  • Capital Analysts LLC first reported a position in Verrica Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Capital Analysts LLC's Verrica Pharmaceuticals position peaked at $12K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.